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Edited by Takashi GojoboriAbstract Basic ﬁbroblast growth factor (bFGF) was inserted in
the middle of human ribonuclease 1 (RNase1) sequence at an
RNase inhibitor (RI)-binding site (Gly89) by a new gene fusion
technique, insertional-fusion. The resultant insertional-fusion
protein (CL-RFN89) was active both as bFGF and as RNase.
Furthermore, it acquired an additional ability of evading RI
through steric blockade of RI-binding caused by fused bFGF
domain. As a result, CL-RFN89 showed stronger growth
inhibition on B16/BL6 melanoma cells than an RI-sensitive
tandem fusion protein. Thus, the insertional-fusion technique
increases accessible positions for gene fusion on RNase, resulting
in construction of a potent cytotoxic RNase.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Several kinds of hybrid proteins have been constructed to
produce bifunctional proteins and utilized as tools such as
detectors for biological molecules. Generally, those hybrid
proteins have been built by end-to-end fusion (tandem-fusion)
of two genes of component proteins. The alternative is to insert
the second protein (the insert protein) into the middle of the
sequence of the host protein in-frame [1,2]. This new mode of
gene fusion (insertional-fusion) is expected to give an addi-
tional conﬁguration between two component domains and to
make it possible to create the hybrid protein with the ideal 3D
structure for new functions. However, the insertional-fusion
has not been popular because it is apparently more limited and
requires precise information on the parental protein structures.
Therefore, insertional-fusion has ﬁrst been achieved by ran-
dom screening to ﬁnd accessible site for insert sequences [3].* Corresponding author. Fax: +81-86-251-8265/8216.
E-mail address: tadahrk@biotech.okayama-u.ac.jp (H. Tada).
Abbreviations: bFGF, basic ﬁbroblast growth factor; CL-RNase1, 4-
118 cross-linked RNase1 mutant; RFNs, insertional-fusion proteins
between hRNase1 and bFGF; CL-RFNs, insertional-fusion proteins
between CL-RNase1 and bFGF; RI, ribonuclease inhibitor
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structures to very large protein insertions is more general than
previously thought [4], and some insertional-fusion proteins
have been designed based on the 3D structures of component
proteins and successfully obtained in active structures. How-
ever, the resultant proteins were less stable than the parental
proteins (reviewed in [2]).
We used this insertional-fusion technique for engineering
human RNase1 to be cytotoxic. RNase1 itself is not cytotoxic
as a majority of RNase superfamily. The major reasons con-
sidered for it are (1) the neutralization of their ribonucleolytic
activity by RNase inhibitor (RI) expressed ubiquitously in the
cytosol [5], and (2) insuﬃcient binding to the target cells.
Therefore, engineered variants of RNase1, which could eﬃ-
ciently reach the cytosol of the target cells [6,7] and/or to
maintain their activity there by evading the action of RI [8],
were reported to acquire cytotoxicity. Previously, we con-
structed cytotoxic RNase by fusing human basic ﬁbroblast
growth factor (bFGF) to the C-terminus of RNase1 [9]. The
resultant tandem-fusion protein (RNF) could inhibit the
growth of malignant cells with high levels of cell surface FGF
receptor. However, its activity was still weak (IC50 value was
more than 1 lM) probably because it could not evade inacti-
vation by RI.
In this study, bFGF was inserted into RNase1 at the exact
RI-binding site that is in the middle of RNase sequence. The
resultant insertional-fusion protein had both abilities of eﬃ-
cient binding to target cells and evading RI by masking the RI
interaction site with the targeting protein of bFGF. Further-
more, an additional intramolecular disulﬁde-bridge was in-
troduced in the insertional-fusion protein to increase its
conformational stability that was suggested as another im-
portant determinant of RNase-mediated cytotoxicity [10,11].
These insertional-fusion proteins were evaluated for activities
of both RNase and bFGF, for stability against protease di-
gestion, and for growth inhibition on malignant cells.2. Materials and methods
2.1. Materials
Recombinant human RNase1, 4–118 cross-linked RNase 1 (CL-
RNase 1) and human bFGF (147 amino acid form) were puriﬁed from
Escherichia coli as described previously [9,12].blished by Elsevier B.V. All rights reserved.
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A cDNA encoding bFGF (19–146) (N-terminal 18 residue-truncated
form of bFGF) was ampliﬁed by polymerase chain reaction using
primers (50-TTTCCGCGGGCAGCGACCCCAAGCGGCTGTAC-
30) and 50-ATTCCGCGGAGCTTTCAGCAGACATTGG-30) and
pBO126 [9] as a template. On the other hand, a SacII site was intro-
duced at the position of Pro19 or Gly89 of RNase1 cDNA into an
RNase1 expression vector of pBO26 [13] by site-directed mutagenesis.
The resultant plasmids were cleaved with SacII and ligated in-frame
with the SacII fragment of bFGF (19–146) to construct the expression
vectors for insertional-fusion proteins with bFGF insertion at Pro19
(RFN19) or at Gly89 (RFN89) of RNase1, respectively. Similarly, the
expression vectors for fusion proteins with bFGF (19–146) insertion at
Pro19 (CL-RFN19) or at Gly89 (CL-RFN89) of CL-RNase1 were
constructed using an expression vector for CL-RNase1, pBO383 [12],
instead of pBO26. The expression vector for an insertional-fusion
protein with bFGF (21–144) insertion at Gly89 of CL-RNase1 (CL-
RFN89-2) was also constructed by insertion of the bFGF (21–144)
fragment ampliﬁed with primers (50-ATACCGCGGCCAAGCG-
GCTGTAC-30 and 50-AGCCCGCGGCAGACATTGGAAG-30). The
schematic structures of these RFNs and CL-RFNs are depicted in
Fig. 1A.
2.3. Expression, refolding and puriﬁcation of insertional-fusion proteins
All of the insertional-fusion and tandem-fusion proteins were ex-
pressed as inclusion bodies in E. coli, and then solubilized, refolded,
and puriﬁed by the same procedure as described previously [13,14].
The puriﬁed proteins were concentrated by ultraﬁltration with Ultra-
free-4 centrifugal ﬁlter (Biomax-5K NMWL, Millipore, USA). Protein
concentrations were determined by UV spectroscopy as described [15].
2.4. Assays for RNase activity
Ribonucleolytic activity of the insertional-fusion proteins on yeast
transfer RNA was measured as described previously [16]. To evaluate
the aﬃnity of RI for each protein, their RNase activity was measured
in the presence and absence of 130 units/ml of recombinant humanFig. 1. The schematic structures of insertional-fusion proteins between
bFGF and RNase1. (A) The bFGF (white bar) was inserted in host
RNase1 (striped bar) by gene fusion. Black bars indicate linker se-
quences derived from restriction sites for insertion. The positions of
additional disulﬁde cross-link and introduced cystein residues are
shown. (B) Model of CL-RFN89. The structure derived from RNase1
(PDB No. 1UFS, unpublished data) is dark gray and that from bFGF
(PDB No. 2FGF [27]) is light gray. This ﬁgure was produced using the
RasMac molecular graphics program, version 2.6 [28]. The amino acid
residue numbers derived from RNase1 sequence are indicated in pa-
renthesis and those from bFGF are underlined. Extra methionine
residues at )1 positions of these proteins derived from the initiation
codons were all conﬁrmed by N-terminal amino acid sequence analy-
sis, and indicated as ()1).placental RI (Wako, Japan) (1 unit of RI is that amount required to
inhibit 50% the activity of 5 ng of RNase A) and 1 mM DTT.
2.5. Mitogenic activity toward serum-starved murine ﬁbroblasts
Mouse Balb/c 3T3 A31 cells were grown in Dulbecco’s modiﬁed
Eagle’s medium (DMEM; Nissui, Japan) containing 10% fetal bovine
serum (FBS). The cells were plated onto 96-well plates (1.5 103 cells/
well) and cultured for 12h. The medium was then replaced with
DMEM containing 0.5% FBS (100 ll) and the cells were incubated for
1 day to starve the cells. Then, 100 ll of samples was added to the
wells. After 2 days of cultivation, the cell growth was measured with 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as
described previously [17].
2.6. Assays for growth inhibitory eﬀect
Cytotoxicity on mouse metastatic melanoma B16/BL6 cells was
evaluated as described previously [9].
2.7. Tryptic digestion
Digestion of each protein was carried out under the physiological
conditions with trypsin [12]. Five lg of proteins dissolved in 15 ll of 75
mM Tris–HCl, pH 8.0, was incubated with indicated concentrations of
TPCK–trypsin at 37 C for 30 min. The reactions were stopped by
addition of a sample buﬀer and analyzed by SDS–PAGE on 15%
polyacrylamide gel under reducing conditions.3. Results and discussion
3.1. Design of insertional-fusion proteins between RNase1 and
bFGF
Previous studies on native cytotoxic RNases as well as
engineered cytotoxic RNases have shown that the mechanism
of RNase-mediated cytotoxicity consists of two steps: binding
to the target cells to reach cytosol and catalytic cleavage of
cellular RNA. If a targeting protein can be fused at the exact
site of RI-binding on the RNase1 molecule, the resultant
fusion protein is expected to show cytotoxicity through both
abilities of eﬃcient cell binding and eﬃcient ribonucleolytic
activity in the cytosol in which RI is ubiquitously expressed.
However, it is impossible to construct such a structure by the
conventional tandem-fusion technique, because both termini
of RNase are apart from the RI-binding sites. Previously,
Suzuki et al. conjugated a targeting protein (transferrin) with
RNase1 at the RI-binding site via a thioether bond [18] with
an aim similar to ours and successfully obtained a cytotoxic
RNase. In this study, we used insertional-fusion technique to
place a targeting protein at the RI-binding site. On the design
of insertional-fusion proteins, we selected bFGF as a tar-
geting protein for insertion, since the N- and C-termini of
‘‘beta-trefoil core region (residues 19–146)’’ of bFGF are near
each other (5.3 A between Cas of Asp19 and Lys145) as
shown in Fig. 1B. This fragment has been shown to be suf-
ﬁcient for its biological activities [19]. On the other hand, an
RI-binding site of Gly89 [20] was selected as the insertion site
on RNase1. Pro19 irrelevant to RI-binding was also selected
as another insertion site for control. Taken together, we
constructed two insertional-fusion proteins of RFN89 and
RFN19, respectively (Fig. 1A). Furthermore, we constructed
two additional insertional-fusion proteins named CL-RFN89
and CL-RFN19 using a stabilized mutant of RNase1 (CL-
RNase1) as a host, to obtain more stable insertional-fusion
proteins. In CL-RNase1, two cystein residues introduced at
positions 4 and 118 of RNase1 form an additional intramo-
lecular disulﬁde cross-link to stabilize its structure [12]. Fur-
thermore, CL-RFN89-2 was constructed by inserting bFGF
Fig. 2. Enzymatic activity of the insertional-fusion proteins in the
presence of RI. Inhibition of ribonucleolytic activity of the insertional-
fusion proteins by RI was assayed with tRNA as a substrate. Re-
maining activity (%) is indicated as relative activity in the presence of
RI (a molar ratio of enzyme to inhibitor of 1:200–300) to that in the
absence of RI. The values were meansS.D. of three experiments.
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sequences.
3.2. Activities of RNase domain and bFGF domain of
insertional-fusion proteins
When these insertional-fusion proteins were expressed di-
rectly in E. coli, they were produced as inclusion bodies. After
refolding, the yields of all the insertional-fusion proteins pu-
riﬁed from 1 liter-culture were about the same, from 5 to 10
mg. As shown in Table 1, all of these insertional-fusion pro-
teins were ribonucleolytically active (30% or more of wild-type
RNase1). The results indicate that their RNase domains were
properly folded as the parental RNase1, nevertheless their
primary sequences are divided and intervened by long bFGF
sequence.
To access their actual activity under cytosolic conditions,
RNase activity was measured in the presence of RI (Fig. 2).
RNase activity of RFN19, CL-RFN19, and RNF was com-
pletely inhibited by RI as RNase1 was. In contrast, RFN89,
CL-RFN89, and CL-RFN89-2 retained their activity by 85%
or more even in the presence of 200-fold molar excess amount
of RI. From these results, the values of inhibitor constant (Ki)
of RFN89, CL-RFN89 and CL-RFN89-2 to RI were esti-
mated to be approximately 100–200 nM (Table 1), which were
104-fold higher than that of wild-type RNase1 (Ki ¼ 20 pM
[21]). Thus, the insertional-fusion proteins with bFGF inser-
tion at the RI-binding site of RNase1 acquired the ability of
evading RI.
Mitogenic activity of these insertional-fusions was accessed
to evaluate the activity of bFGF domain (Table 1). All the
insertional-fusion proteins showed strong mitogenic activity as
much as the tandem RNF. Thus, the bFGF domain is also
properly folded in the middle of RNase1 sequence to bind cell-
surface FGF-receptors.3.3. Stability of insertional-fusion proteins against tryptic
digestion
The conformational stability of RNases was suggested as
another important factor for their cytotoxic activity [10,11].
However, in general, ‘‘insertional-fusion proteins’’ have been
shown to be less stable than the parental proteins [4]. In the
case of another insertional-fusion protein between SH3 do-
main and protein L, the free energy for unfolding of SH3 wasTable 1
Characteristic properties of the insertional-fusion proteins between RNase1
Proteins RNase activity Inhibitor constant
(%)a Ki (nM)b
RNF 84.8 3.5 2.1 0.8
RFN19 50.2 3.2 4.7 1.4
RFN89 68.2 9.1 1.3 0.3
CL-RFN19 76.0 7.4 118 9.8
CL-RFN89 36.8 4.6 110 51
CL-RFN89-2 33.1 1.5 193 34
HRNase1 100 <1
CL-RNase 38.9 1.8 1.8 0.8
bFGF – –
aRibonucleolytic activity was measured at 37 C by using yeast transfer RNA
b Inhibitor constant to RI was calculated from the data shown in Fig. 2, as
cMouse ﬁbroblast Balb/c 3T3 A31 cells were cultured with various proteins
measured by the MTT assay.
dMouse B16/BL6 melanoma cells were cultured with various proteins for 3
eNot detected.reported to be reduced by 1.2 kcal/mol [22]. We therefore
evaluated the stability of the insertional-fusion proteins by
tryptic digestion. As shown in Fig. 3, the insertional-fusion
proteins were digested faster than the tandem-RNF and pa-
rental RNase1, indicating that their structures are considerably
destabilized. RFN89 was less stable than RFN19 in spite of
same length and sequence of the insert, suggesting that some
signiﬁcant destabilization such as conformational strain might
be associated with RFN89. Thus, although RFN89 was ob-
tained as active form, it was considered to be too unstable to
resist proteolytic digestion systems in the target cells. CL-
RFNs, in which an additional intramolecular disulﬁde-bridge
was introduced to stabilize their structure, were more stable
than the respective RFNs, although they were still less stable
than the tandem-RNF. As another attempt, both of the spacer
sequences between host and insert domains were shortened by
two residues in CL-RFN89-2 (Fig. 1A), however, obvious
additional stabilization or destabilization was not observed in
the tryptic digestion assay (data not shown). Similar results
were obtained by using proteinase K instead of trypsin, sug-
gesting that the increased protease-sensitivity was not sequence
speciﬁc but resulted from the decreased conformational sta-
bility of these fusion proteins because protease digestion of
small globular proteins generally occurs from the unfoldedand bFGF
Mitogenic activity Growth inhibition
ED50 (pM)
c IC50 (lM)d
18.6 16.5 1.6 0.8
9.5 6.8 1.5 1.1
26.0 15.3 0.87 0.30
8.7 5.4 >3
6.7 3.0 0.32 0.14




as a substrate and expressed as relative activity (%) to that of RNase1.
described previously [16].
under low-serum (0.5%) conditions. After 3 days, the cell growth was
days. The growth of the cells was measured by the MTT assay.
Fig. 4. Growth inhibitory eﬀects of the insertional fusion proteins on
mouse melanoma B16/BL6 cells. B16/BL6 cells (5 102 cells/well) were
cultured for 3 days with RNF (open triangle), RFN19 (open circle),
RFN89 (open square), CL-RFN19 (solid circle), CL-RFN89 (solid
triangle), and CL-RFN89-2 (solid square), respectively. Cell growth of
each well was monitored by MTT assay. Each point and vertical line
show the mean value and the S.D. of triplicates, respectively.
Fig. 3. SDS–PAGE analysis of digestion of the insertional-fusion
proteins with trypsin under physiological conditions. The insertional-
fusion proteins were incubated in the presence of various concentra-
tions of trypsin at pH 8.0 and 37 C for 30 min, and then subjected to
SDS–PAGE. The concentrations of trypsin were 0 lg/ml (lane 1), 0.5
lg/ml (lane2), 1.0 lg/ml (lane 3), 2.1lg/ml (lane 4), and 4.2 lg/ml (lane
5), respectively. Panels A, hRNase1; B, RNF; C, RFN19; D, CL-
RFN19; E, RFN89; F, CL-RFN89, respectively. Bars on the right
show the positions of some molecular protein size markers.
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[23,24]. The results from the N-terminal sequence analysis of
the partially digested fragments of the RFNs indicated that the
host domain was much less stable than the insert domain and
thus the digestion occurred preferentially in the host domain
(data not shown). This suggested that the host domain (RN-
ase) was preferentially destabilized in the RFNs. Although the
insert domain was also destabilized to be digested faster than
bFGF itself, the eﬀect to the host domain is considered more
signiﬁcant than the insert domain. Considering the unstable
nature of RFN89, RNase1 is thought to have only enough
conformational stability (5.7 kcal/mol [12]) to tolerate inser-
tional-fusion. On the other hand, when an intramolecular di-
sulﬁde-bridge was introduced in RNase1, the conformational
stability of the resultant mutant of CL-RNase1 increased by
approximately 2 kcal/mol [12]. These observations suggest that
introduction of additional intramolecular disulﬁde bridges
would be a general and eﬀective strategy against destabiliza-
tion associated with insertional-fusion.
3.4. Growth inhibition by insertional-fusion proteins
All of the insertional-fusion proteins except CL-RFN19
inhibited the growth of B16/BL6 melanoma cells similar to
the tandem-fusion protein RNF (Table 1). As expected, the
activity of the insertional-fusion proteins with higher stability
and RI-evading ability (CL-RFN89 and CL-RFN89-2) was
5- and 7-fold stronger than that of RNF, respectively. In
contrast, RI-sensitive CL-RFN19 showed little growth in-
hibitory eﬀect, although it was more stable and more ribo-
nucleolytically active in the absence of RI than RI-resistant
ones.
In this study, we measured four factors possibly involved in
the growth inhibitory eﬀect of the fusion proteins between
RNase1 and bFGF: RNase activity itself derived from RNase
domain, that in the presence of RI, the mitogenic activityderived from bFGF domain, and the stability against prote-
ases. Among them, the RNase activity in the presence of RI as
a result of the RI-evading ability was indicated as the most
important factor for the growth inhibition. The facts that the
diﬀerence in the inhibitor constant (Ki) values among the fu-
sion proteins (more than 100 nM for RI-evading CL-RFN89s
and less than 5 nM for other RI-sensitive fusion proteins) was
remarkable and the value was relatively close to their IC50
values might be the reasons for the eﬀectiveness (Table 1). In
addition, the structural stability was also suggested to aﬀect
the growth inhibitory activity since the increase in growth in-
hibitory activity of the least stable RFN89 was only slight,
although it showed highest RNase activity in the presence of
RI. These results suggested that the eﬀect of enhanced RNase
activity in the presence of RI was almost completely cancelled
by the rapid decrease of the actual concentration of active
RFN89 in the cells caused by the rapid degradation of unstable
RFN89. In contrast, intrinsic RNase activity is considered to
have little eﬀect on the present growth inhibition, because the
enhancement of RI-evading was more prominent than the
decrease in RNase activity of the fusion proteins (Table 1 and
Fig. 2). As for the targeting ability derived from bFGF, the
lower ED50 values in the mitogenic activity of the fusion
proteins suggested their higher aﬃnity to high aﬃnity tyrosine-
kinase receptors for bFGF but their similar elution proﬁle on
heparin-column HPLC (data not shown) suggested that their
aﬃnity to low-aﬃnity receptors would be equivalent to that of
bFGF. However, this targeting ability also had little eﬀect on
the growth inhibition. The ED50 values of mitogenic activity
(from 0.005 to 0.03 nM) as well as reported aﬃnity of bFGF to
their cell surface receptors (Kd of 0.2 nM for high-aﬃnity re-
ceptors and 9 nM for low-aﬃnity receptors [25]) were ex-
tremely lower than the IC50 values of their growth inhibition
H. Tada et al. / FEBS Letters 568 (2004) 39–43 43(more than 200 nM), suggesting that all of the fusion proteins
already had suﬃcient aﬃnity for their receptors (see Fig. 4).
Considering CL-RFN89 as an anti-cancer cytotoxin, use of
growth factors such as bFGF as a targeting carrier may be
controversial, because it might be possible that their mitogenic
eﬀect could cancel their growth inhibitory eﬀect or cause the
proliferation of the target cancer and/or the normal cells in
vivo. Although little mitogenic eﬀect was observed on Balb/c
3T3 cells as well as B16/BL6 melanoma cells in the normal
culture containing 10% serum (data not shown), this possibility
of CL-RFN89 should be checked by using the individual target
cancer cells as well as normal tissues before therapeutic ap-
plication. This problem will be solved by using antagonistic
bFGF mutants that possess decreased mitogenicity with little
change in aﬃnity for cell surface receptors [26]. Since CL-
RFN89 also inhibits the proliferation of other FGFR-positive
cells such as human vein endothelial cells, the possibility of its
therapeutic application to neovascular diseases is now under
investigation.
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